TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (Hcc) is the fastest growing cause of cancer-related deaths globally. epithelial-to-mesenchymal transition (eMT) is a cellular process that confers Hcc tumor cells with the ability to evade the immune system. immune escape in most tumors, including Hcc, is controlled by immune checkpoint molecules. The aim of the present study was to investigate the association between eMT and immune checkpoint in Hcc, and identify novel therapeutic targets for Hcc. an in vitro model of reversible eMT was utilized based on cytokine tumor necrosis factor (TnF)-α treatment of Hcc cell lines Hep3B and Plc/PrF/5. Hep3B and Plc/PrF/5 cells were treated with TnF-α, and the eMT status and the expression of immune checkpoint molecules was assessed by reverse transcription-quantitative Pcr, western blotting and immunofluorescence. To confirm an association between eMT and immune modulators, cells were exposed to culture medium with TnF-α for 3 days to induce eMT, following which a reversal assay was performed. The expression of immune modulators and mesenchymal-to-epithelial transition (MeT) status was investigated upon reversal of eMT. Furthermore, Survexpress, a web-based platform was utilized to analyze survival and recurrence in a dataset of patients with Hcc. TnF-α treatment for 3 days induced eMT in Hep3B and Plc/PrF/5 cells, as demonstrated by the downregulation of epithelial markers along with upregulation in mesenchymal markers. an eMT reversal assay was able to induce MeT by increasing epithelial markers and decreasing mesenchymal markers. TnF-α-induced eMT led to the upregulation of immune modulators, including programmed death receptor ligand (PD-L)1, PD-L2, CD73 and B7-H3. in contrast, reversal of eMT suppressed the expression of PD-L1, PD-L2, CD73 and B7-H3. in addition, high expression of TnF-α and Pd-l1 in 422 patients with Hcc was associated with poor overall survival. The coordinate expression of TnF-α with Pd-l2 in this patient cohort was associated with increased Hcc recurrence. in conclusion, the present study demonstrated a close association between immune modulator expression and eMT induction/reversal driven by TnF-α.

Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers

“…Another example of tumor-intrinsic immune escape described in HCC involves epithelial-to-mesenchymal-transition (EMT). A study by Shrestha et al investigated the association between EMT and induction of immune checkpoint expression in HCC ( 35 ). TNFalpha induced EMT in Hep3B and PLC/PRF/5 cells and led to the upregulation of PD-L1, PD-L2, CD73, and B7-H3, whereas reversal of EMT (MET) led to suppression of these markers ( 35 ).…”

“…A study by Shrestha et al investigated the association between EMT and induction of immune checkpoint expression in HCC ( 35 ). TNFalpha induced EMT in Hep3B and PLC/PRF/5 cells and led to the upregulation of PD-L1, PD-L2, CD73, and B7-H3, whereas reversal of EMT (MET) led to suppression of these markers ( 35 ). In a cohort of 422 HCC patients, they demonstrated that high expression of TNFalpha and PD-L1 is associated with poor overall survival and expression of TNFalpha and PD-L2 was associated with increased HCC recurrence ( 35 ).…”

Purinergic Signaling in the Hallmarks of Cancer

“…Additionally, it has been observed that HIF-1 binds the NT5E gene promoter, confirming that hypoxia is a strong regulator of immune checkpoints dependent on ADO [ 20 ]. In a model of induction and reversion of EMT in hepatocellular carcinoma, TNF-〈 induced overexpression of the NT5E gene and reversion of EMT downregulation [ 176 ]. In agreement, a bioinformatics analysis using the gene Signature Finder Algorithm (gSFA) found in colorectal cancer that NT5E belongs to the gene signature of this disease, and that it is a transcriptional target of TNF-〈 [ 177 ].…”

Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma

“…In recent years, EMT has been closely associated with expression and regulation of immune checkpoint molecules in several cancers including lung cancer [18][19][20][21][22], breast cancer [23][24][25][26], oesophageal cancer [27], gastric cancer [27][28][29], salivary adenoid cystic carcinoma [30], pancreatic cancer [31,32] and head and neck cancer [33]. Previously, we reported an association between the process of EMT and the expression of several immune checkpoint molecules including PD-L1 in HCC [11,34]. Notably, in HCC patients a close association between EMT and immune checkpoint molecules prognosticated a poor survival [11,34].…”

“…We have previously shown that cytokine, tumour necrosis factor (TNF)-α, regulates expression of immune checkpoint molecules in HCC [34]. In this study, we have used another cytokine, transforming growth factor (TGF)-β1, which is a potent inducer of EMT in HCC cells [35][36][37].…”